IVERIC bio, Inc. – NASDAQ:ISEE
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 9 hours
IVERIC bio stock price monthly change
+5.58%
month
IVERIC bio stock price quarterly change
+63.63%
quarter
IVERIC bio stock price yearly change
+314.47%
year
IVERIC bio key metrics
Market Cap | 5.51B |
Enterprise value | 2.96B |
P/E | -17.71 |
EV/Sales | N/A |
EV/EBITDA | -16.22 |
Price/Sales | N/A |
Price/Book | 6.25 |
PEG ratio | 0.48 |
EPS | -1.67 |
Revenue | N/A |
EBITDA | -231.35M |
Income | -212.13M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeIVERIC bio stock price history
IVERIC bio stock forecast
IVERIC bio financial statements
| Jun 2022 | 0 | -48.29M | |
|---|---|---|---|
| Sep 2022 | 0 | -41.95M | |
| Dec 2022 | 0 | -51.27M | |
| Mar 2023 | 0 | -70.61M |
| 2023-05-15 | -0.59768 | -0.53 |
|---|
| Jun 2022 | 319756000 | 26.81M | 8.38% |
|---|---|---|---|
| Sep 2022 | 331790000 | 72.26M | 21.78% |
| Dec 2022 | 666823000 | 132.16M | 19.82% |
| Mar 2023 | 613407000 | 136.36M | 22.23% |
| Jun 2022 | -35.90M | -17.64M | 2.80M |
|---|---|---|---|
| Sep 2022 | -41.11M | 3.38M | 49.71M |
| Dec 2022 | -49.23M | -1.86M | 374.30M |
| Mar 2023 | -50.59M | 39.27M | 2.58M |
IVERIC bio alternative data
| Aug 2023 | 163 |
|---|---|
| Sep 2023 | 163 |
| Oct 2023 | 163 |
| Nov 2023 | 163 |
| Dec 2023 | 163 |
| Jan 2024 | 163 |
| Feb 2024 | 163 |
| Mar 2024 | 163 |
| Apr 2024 | 163 |
| May 2024 | 163 |
| Jun 2024 | 163 |
| Jul 2024 | 163 |
IVERIC bio other data
94.68%
-5.32%
of ISEE is owned by hedge funds
195
+14
113.31M
-5.96M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 0 | 12272 |
| Nov 2022 | 0 | 122916 |
| Dec 2022 | 0 | 62910 |
| Jan 2023 | 0 | 26897 |
| Feb 2023 | 0 | 51214 |
| Mar 2023 | 0 | 20000 |
| Apr 2023 | 0 | 110000 |
| May 2023 | 0 | 94714 |
| Jun 2023 | 0 | 20000 |
| Jul 2023 | 0 | 20000 |
| Patent |
|---|
Application Filling date: 21 Feb 2022 Issue date: 9 Jun 2022 |
Application Filling date: 14 Jun 2021 Issue date: 2 Dec 2021 |
Application Filling date: 16 Nov 2018 Issue date: 10 Jun 2021 |
Application Filling date: 6 Jun 2019 Issue date: 19 Dec 2019 |
| Quarter | Transcript |
|---|---|
| Q4 2022 1 Mar 2023 | Q4 2022 Earnings Call Transcript |
| Q3 2022 5 Nov 2022 | Q3 2022 Earnings Call Transcript |
| Q2 2022 26 Jul 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 4 May 2022 | Q1 2022 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
Mr. Glenn P. Sblendorio M.B.A. (1956) Chief Executive Officer & Director | $1,250,000 |
| Dr. Pravin U. Dugel M.D. (1964) Pres | $780,650 |
| Mr. David F. Carroll (1966) Senior Vice President, Chief Financial Officer & Treasurer | $633,580 |
Mr. Keith Westby M.B.A. (1975) Senior Vice President & Chief Operating Officer | $621,220 |
Apellis Pharmaceuticals Is Poised For Dominance In Geographic Atrophy Market
Iveric Bio: ACP Advances As GATHER Results Continue To Impress
Apellis Pharmaceuticals: Approval Is Baked Into Valuation
Iveric bio: Building Momentum Around Zimura, Rate Buy
Iveric bio: Further Upside Possible Based On Expanded Opportunities With Zimura
IVERIC bio: A First Take
Biopharmaceutical Stocks: The Bottoming Process Is Playing Out
Learning Lessons From 3 Stocks Flourishing In A Desperate Biotech Bear Market
Apellis' Loss Is Iveric Bio's Gain In Lucrative Eye Disease Field
-
When is IVERIC bio's next earnings date?
Unfortunately, IVERIC bio's (ISEE) next earnings date is currently unknown.
-
Does IVERIC bio pay dividends?
No, IVERIC bio does not pay dividends.
-
How much money does IVERIC bio make?
IVERIC bio has a market capitalization of 5.51B. IVERIC bio made a loss 175.75M US dollars in net income (profit) last year or -$0.53 on an earnings per share basis.
-
What is IVERIC bio's stock symbol?
IVERIC bio, Inc. is traded on the NASDAQ under the ticker symbol "ISEE".
-
What is IVERIC bio's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of IVERIC bio?
Shares of IVERIC bio can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are IVERIC bio's key executives?
IVERIC bio's management team includes the following people:
- Mr. Glenn P. Sblendorio M.B.A. Chief Executive Officer & Director(age: 69, pay: $1,250,000)
- Dr. Pravin U. Dugel M.D. Pres(age: 61, pay: $780,650)
- Mr. David F. Carroll Senior Vice President, Chief Financial Officer & Treasurer(age: 59, pay: $633,580)
- Mr. Keith Westby M.B.A. Senior Vice President & Chief Operating Officer(age: 50, pay: $621,220)
-
How many employees does IVERIC bio have?
As Jul 2024, IVERIC bio employs 163 workers.
-
When IVERIC bio went public?
IVERIC bio, Inc. is publicly traded company for more then 12 years since IPO on 25 Sep 2013.
-
What is IVERIC bio's official website?
The official website for IVERIC bio is ivericbio.com.
-
Where are IVERIC bio's headquarters?
IVERIC bio is headquartered at 8 Sylvan Way, Parsippany, NJ.
-
How can i contact IVERIC bio?
IVERIC bio's mailing address is 8 Sylvan Way, Parsippany, NJ and company can be reached via phone at +60 9 474 6755.
IVERIC bio company profile:
IVERIC bio, Inc.
ivericbio.comExchange:
NASDAQ
Full time employees:
163
Industry:
Biotechnology
Sector:
Healthcare
IVERIC bio, Inc., a biopharmaceutical company, discovers and develops novel treatments for retinal diseases with a focus on age-related and orphan inherited retinal diseases (IRDs). The company develops Zimura, an inhibitor of complement factor C5 comprising GATHER1, which has completed Phase 2/3 clinical trial; and GATHER2 that is in Phase 3 clinical trial for the treatment of geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). It also develops STAR or OPH2005 that is in Phase 2b clinical trial for the treatment of leber congenital amaurosis type 10 (LCA10) and autosomal recessive stargardt disease (STGD1); IC-500, a high temperature requirement A serine peptidase 1 protein inhibitors for the treatment of GA and other age-related retinal diseases; IC-100 for the treatment of rhodopsin-mediated autosomal dominant retinitis pigmentosa; and IC-200 for the treatment of IRDs associated with mutations in the BEST1 gene. In addition, the company develops OPH2001 that has completed Phase 1/2a clinical trial of various doses of Zimura monotherapy for the treatment of GA; OPH2000, which has completed Phase 1/2a clinical trial of various doses of Zimura administered in combination with Lucentis for the treatment of wet AMD; OPH2007 that has completed Phase 2a clinical trial for the treatment of wet AMD; and OPH2002, which has completed Phase 2a clinical trial for the treatment of idiopathic polypoidal choroidal vasculopathy. Its discovery and research programs include miniCEP290 program for LCA10; miniABCA4 Program for STGD1; and miniUSH2A Program for usher syndrome type 2A-Related IRDs. The company was formerly known as Ophthotech Corporation and changed its name to IVERIC bio, Inc. in April 2019. The company was incorporated in 2007 and is based in Parsippany, New Jersey.
8 Sylvan Way
Parsippany, NJ 07054
Parsippany, NJ 07054
CIK: 0001410939
ISIN: US46583P1021
CUSIP: 46583P102
